Diarrhea News and Research

Latest Diarrhea News and Research

ATN study shows prevalence of GI symptoms in children with ASD

Parents of children and adolescents with autism spectrum disorders sometimes report that their children suffer from gastrointestinal symptoms, such as diarrhea and constipation. However, studies on how prevalent these symptoms are have had conflicting results.

3 May 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Nuvo Research's PENNSAID now available in U.S. pharmacies

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.

27 Apr 2010

IBS patients treated with cognitive behavior therapy have positive response: Study

A significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

27 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder's Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

26 Apr 2010

Promising research on cryptosporidiosis could lead to effective treatment: Brandeis University biochemist

Discovered in 1976, cryptosporidium lurks worldwide in water, contaminating swimming pools, water parks, and drinking water supplies. Although it has even been featured on the comedy show The Colbert Report, it is no laughing matter-this microscopic pathogen is a leading cause of diarrhea and malnutrition and the most common source of infection in immune-weakened people such as AIDS patients.

26 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

CryoSTAT cold therapy for hemorrhoids

Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.

20 Apr 2010

House markup of supplemental spending bill that includes Haiti relief delayed one week

A supplemental spending bill that is expected to include earthquake relief aid for Haiti will be considered by the full House Defense Appropriations Subcommittee during the week of April 26 and will not be written this week as several aides and members had anticipated, C.W. Bill Young, the committee's ranking Republican from Florida, said, CQ Today reports.

20 Apr 2010

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

19 Apr 2010

Budget impact of traditional fecal management methods to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new study results that demonstrate hospitals could realize substantial savings by substituting Flexi-Seal FMS for traditional fecal management methods.

19 Apr 2010

Diarrhea News and Research

Latest Diarrhea News and Research

ATN study shows prevalence of GI symptoms in children with ASD

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Nuvo Research's PENNSAID now available in U.S. pharmacies

IBS patients treated with cognitive behavior therapy have positive response: Study

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Covidien introduces PENNSAID to the U.S. market

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Promising research on cryptosporidiosis could lead to effective treatment: Brandeis University biochemist

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

CryoSTAT cold therapy for hemorrhoids

House markup of supplemental spending bill that includes Haiti relief delayed one week

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Budget impact of traditional fecal management methods to be presented at SAWC/WHS 2010

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diarrhea News and Research

Latest Diarrhea News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in